UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Cancer, ISSN 0008-543X, 04/2019, Volume 125, Issue 7, pp. 1101 - 1112
competing risks | non‐Hodgkin lymphoma | histologic subtype | comorbidity | aging | non-Hodgkin lymphoma | Life Sciences & Biomedicine | Oncology | Science & Technology | SEER Program | Medicare | Comorbidity | United States | Humans | Lymphoma, Follicular - mortality | Male | Cause of Death | Lymphoma, B-Cell, Marginal Zone - mortality | Burkitt Lymphoma - mortality | Incidence | Lymphoma, Large B-Cell, Diffuse - mortality | Lymphoma, Mantle-Cell - mortality | Skin Neoplasms - mortality | Aged, 80 and over | Female | Aged | Lymphoma, Non-Hodgkin - mortality | Mycosis Fungoides - mortality | Waldenstrom Macroglobulinemia - mortality | Lymphoma, T-Cell, Peripheral - mortality | Health care | Mycosis | Decision making | Mortality | Mycosis fungoides | Epidemiology | Patients | Lymphoma | Government programs | Diagnosis | Health risk assessment | Age | Hodgkin's disease | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
British journal of cancer, ISSN 0007-0920, 02/2012, Volume 106, Issue 5, pp. 988 - 995
radiotherapy | non-Hodgkin lymphoma | socioeconomic position | chemotherapy | immunotherapy | survival | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Prognosis | Health Status Disparities | Humans | Middle Aged | Male | Treatment Outcome | Lymphoma, Non-Hodgkin - epidemiology | Survival | Socioeconomic Factors | Lymphoma, Non-Hodgkin - therapy | Aged, 80 and over | Denmark - epidemiology | Healthcare Disparities | Adult | Female | Aged | Lymphoma, Non-Hodgkin - mortality | Cohort Studies | Index Medicus | Epidemiology
Journal Article
Cancer epidemiology, biomarkers & prevention, ISSN 1055-9965, 01/2016, Volume 25, Issue 1, pp. 174 - 179
Oncology | Public, Environmental & Occupational Health | Life Sciences & Biomedicine | Science & Technology | United States - epidemiology | SEER Program | Prognosis | Age Factors | Follow-Up Studies | Humans | Lymphoma, Follicular - diagnosis | Lymphoma, Follicular - mortality | Survival Rate | Mortality - trends | Lymphoma, T-Cell, Peripheral - epidemiology | Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology | Incidence | Lymphoma, Large B-Cell, Diffuse - mortality | Lymphoma, Large B-Cell, Diffuse - diagnosis | Lymphoma, Follicular - epidemiology | Lymphoma, T-Cell, Peripheral - diagnosis | Lymphoma, Large B-Cell, Diffuse - epidemiology | Adult | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Neoplasm Staging | Lymphoma, T-Cell, Peripheral - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis | Index Medicus | Histologic Subtypes | Incidence-based mortality | Non-Hodgkin lymphoma tumor subtype trends | Partition mortality trends | SEER Registries
Journal Article
American journal of hematology, ISSN 0361-8609, 09/2015, Volume 90, Issue 9, pp. 790 - 795
Life Sciences & Biomedicine | Hematology | Science & Technology | United States | Humans | Middle Aged | Lymphoma, Follicular - diagnosis | Lymphoma, Mantle-Cell - pathology | Leukemia, Hairy Cell - mortality | Male | Lymphoma, B-Cell, Marginal Zone - mortality | Burkitt Lymphoma - mortality | Burkitt Lymphoma - pathology | Lymphoma, Mantle-Cell - mortality | Lymphoma, Mantle-Cell - diagnosis | Lymphoma, Large-Cell, Anaplastic - diagnosis | Adult | Female | Lymphoma, B-Cell, Marginal Zone - pathology | B-Lymphocytes - pathology | T-Lymphocytes - pathology | Leukemia, Hairy Cell - pathology | Databases, Factual | Lymphoma, Follicular - pathology | Lymphoma, Follicular - mortality | Terminology as Topic | Burkitt Lymphoma - diagnosis | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Lymphoma, Large-Cell, Anaplastic - mortality | Leukemia, Hairy Cell - diagnosis | Lymphoma, B-Cell, Marginal Zone - diagnosis | Survival Analysis | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Lymphoma, Large-Cell, Anaplastic - pathology | Longitudinal Studies | Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis | Databases | Non-Hodgkin's lymphomas | Native Americans | T cells | Analysis | Leukemia | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 22, pp. 3406 - 3413
Life Sciences & Biomedicine | Hematology | Science & Technology | Humans | Middle Aged | Salvage Therapy | Quinazolinones - administration & dosage | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Purines - administration & dosage | Neoplasm Grading | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Purines - adverse effects | Purines - therapeutic use | Lymphoma, Non-Hodgkin - drug therapy | Quinazolinones - pharmacokinetics | Purines - pharmacokinetics | Treatment Outcome | Class Ia Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Aged | Lymphoma, Non-Hodgkin - mortality | Quinazolinones - therapeutic use | Quinazolinones - adverse effects | Lymphoma, Non-Hodgkin - diagnosis | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
International journal of cancer, ISSN 0020-7136, 02/2020, Volume 146, Issue 4, pp. 970 - 976
prognostic grouping | second cancers | familial risk | prevention | survival | Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Kaplan-Meier Estimate | Family Health | Female | Male | Neoplasms, Second Primary - mortality | Lymphoma, Non-Hodgkin - mortality | Sweden - epidemiology | Neoplasms, Second Primary - pathology | Lymphoma, Non-Hodgkin - pathology | Databases, Factual | Health risks | Risk reduction | Family medical history | Risk analysis | Lymphoma | Survival | Risk factors | Medical prognosis | Genetics | Risk management | Hodgkin's disease | Target detection | Cancer | Index Medicus | Hälsovetenskap | Medical and Health Sciences | Medicin och hälsovetenskap | Public Health, Global Health, Social Medicine and Epidemiology | Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Cancer och onkologi | Health Sciences
Journal Article
Mayo Clinic proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 8, pp. 1152 - 1163
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lymphoma, Non-Hodgkin - mortality | Prognosis | Neoplasm Staging | Lymphoma, Non-Hodgkin - therapy | Humans | Lymphoma, Non-Hodgkin - diagnosis | Complications and side effects | Care and treatment | Stem cells | Transplantation | Non-Hodgkin's lymphomas | Diagnosis | Research | Health aspects | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 01/2013, Volume 119, Issue 2, pp. 371 - 379
angioimmunoblastic T-cell lymphoma | not otherwise specified | peripheral T-cell lymphoma | anaplastic lymphoma kinase-negative anaplastic large cell lymphoma | multidrug resistant proteins | chemotherapy | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Lymphoma, T-Cell, Peripheral - drug therapy | Deoxycytidine - administration & dosage | Humans | Middle Aged | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Etoposide - administration & dosage | Male | Treatment Outcome | Cisplatin - administration & dosage | Young Adult | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - metabolism | Lymphoma, T-Cell, Peripheral - pathology | Aged, 80 and over | Adult | Female | Aged | Neoplasm Staging | Lymphoma, T-Cell, Peripheral - mortality | Deoxycytidine - analogs & derivatives | Methylprednisolone - administration & dosage | Antimitotic agents | T cell lymphoma | Patient outcomes | Dosage and administration | Research | Drug therapy | Antineoplastic agents | Index Medicus | Abridged Index Medicus
Journal Article